STING agonist-primed supramolecular oncolytic hydrogel vaccine for tuning tumors against themselves.

Guo M, Xie S, Jiang C, Tang M, Zhang W, Xiong L, Shang Q, An X, Wang F

Journal of controlled release : official journal of the Controlled Release Society19 May 2026Cited by 4 (Europe PMC)

PMID42155600DOI10.1016/j.jconrel.2026.115032PepBankPUB-42155600

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone11

In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LTX-315.

01AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Efficacy outcome
In vivo, a single vaccination with the combination hydrogel significantly suppressed melanoma tumor growth.
In plain wordsIn a living melanoma model, one combination hydrogel vaccination reduced tumor growth.
Peptide
LTX-315
Outcome
DecreaseMelanoma tumor growth
Study
n: not reported in source
melanoma model
Outcome group
Tumor growth · Cancer
Source sentences
Summary
In vivo studies demonstrated that a single vaccination with the localized hydrogel significantly suppressed tumor growth in both melanoma and colon cancer models.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we report a supramolecular hydrogel vaccine based on the oncolytic peptide LTX-315, designed to locally deliver a STING agonist and thereby mobilize antitumor immunity against the tumor itself.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4215560007
02AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Efficacy outcome
In vivo, a single vaccination with the combination hydrogel significantly suppressed colon cancer tumor growth.
In plain wordsIn a living colon cancer model, one combination hydrogel vaccination reduced tumor growth.
Peptide
LTX-315
Outcome
DecreaseColon cancer tumor growth
Study
n: not reported in source
colon cancer model
Outcome group
Tumor growth · Cancer
Source sentences
Summary
In vivo studies demonstrated that a single vaccination with the localized hydrogel significantly suppressed tumor growth in both melanoma and colon cancer models.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we report a supramolecular hydrogel vaccine based on the oncolytic peptide LTX-315, designed to locally deliver a STING agonist and thereby mobilize antitumor immunity against the tumor itself.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4215560008
03AnimalNot a test of LTX-315 aloneOther designPharmacokinetics
The LTX‑315 and STING agonist hydrogel formed a depot for sustained release after intratumoral injection.
In plain wordsThe LTX‑315 combination hydrogel formed a depot for sustained release after injection into tumors.
Peptide
LTX-315
Outcome
Not applicableSustained peptide release
Study
n: not reported in source
LTX-315 and STING agonist hydrogel vaccine
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Upon intratumoral injection, the in situ forming hydrogel acts as a depot for sustained release of both the oncolytic peptide and STING agonist.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we report a supramolecular hydrogel vaccine based on the oncolytic peptide LTX-315, designed to locally deliver a STING agonist and thereby mobilize antitumor immunity against the tumor itself.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4215560001
04AnimalNot a test of LTX-315 aloneOther designMechanism
In the LTX‑315 and STING agonist hydrogel system, immunogenic cell death occurred.
In plain wordsIn the LTX‑315 combination hydrogel system, cell death stimulated immunity.
Peptide
LTX-315
Outcome
IncreaseImmunogenic cell death
Study
n: not reported in source
LTX-315 and STING agonist hydrogel vaccine
Outcome group
Immune response · Cancer
Source sentences
Summary
LTX-315 induces immunogenic cell death and facilitates the release of autologous tumor antigens, which are subsequently internalized and processed by dendritic cells (DCs) under STING-mediated activation.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we report a supramolecular hydrogel vaccine based on the oncolytic peptide LTX-315, designed to locally deliver a STING agonist and thereby mobilize antitumor immunity against the tumor itself.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4215560002
05AnimalNot a test of LTX-315 aloneOther designMechanism
In the LTX‑315 and STING agonist hydrogel system, autologous tumor antigens were released.
In plain wordsThe LTX‑315 combination hydrogel system released the tumor's own antigens.
Peptide
LTX-315
Outcome
IncreaseAutologous tumor antigen release
Study
n: not reported in source
LTX-315 and STING agonist hydrogel vaccine
Outcome group
Immune response · Cancer
Source sentences
Summary
LTX-315 induces immunogenic cell death and facilitates the release of autologous tumor antigens, which are subsequently internalized and processed by dendritic cells (DCs) under STING-mediated activation.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we report a supramolecular hydrogel vaccine based on the oncolytic peptide LTX-315, designed to locally deliver a STING agonist and thereby mobilize antitumor immunity against the tumor itself.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4215560003
06AnimalNot a test of LTX-315 aloneOther designMechanism
In the combination vaccine system, dendritic cells internalized tumor antigens under STING-mediated activation.
In plain wordsIn the combination vaccine system, dendritic cells absorbed tumor antigens during STING activation.
Peptide
LTX-315
Outcome
Not applicableDendritic cell antigen uptake
Study
n: not reported in source
LTX-315 and STING agonist hydrogel vaccine
Outcome group
Immune response · Cancer
Source sentences
Summary
LTX-315 induces immunogenic cell death and facilitates the release of autologous tumor antigens, which are subsequently internalized and processed by dendritic cells (DCs) under STING-mediated activation.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we report a supramolecular hydrogel vaccine based on the oncolytic peptide LTX-315, designed to locally deliver a STING agonist and thereby mobilize antitumor immunity against the tumor itself.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4215560004
07AnimalNot a test of LTX-315 aloneOther designMechanism
In the combination vaccine system, mature dendritic cells migrated to draining lymph nodes.
In plain wordsIn the combination vaccine system, mature dendritic cells moved to draining lymph nodes.
Peptide
LTX-315
Outcome
Not applicableDendritic cell migration
Study
n: not reported in source
LTX-315 and STING agonist hydrogel vaccine
Outcome group
Immune response · Cancer
Source sentences
Summary
These mature DCs migrate to draining lymph nodes, ultimately eliciting a potent tumor-specific T-cell response.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we report a supramolecular hydrogel vaccine based on the oncolytic peptide LTX-315, designed to locally deliver a STING agonist and thereby mobilize antitumor immunity against the tumor itself.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4215560005
08AnimalNot a test of LTX-315 aloneOther designMechanism
In the combination vaccine system, mature dendritic cell migration elicited a potent tumor-specific T-cell response.
In plain wordsIn the combination vaccine system, dendritic cell migration stimulated T cells against tumors.
Peptide
LTX-315
Outcome
Not applicableTumor-specific T-cell response
Study
n: not reported in source
LTX-315 and STING agonist hydrogel vaccine
Outcome group
Immune response · Cancer
Source sentences
Summary
These mature DCs migrate to draining lymph nodes, ultimately eliciting a potent tumor-specific T-cell response.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we report a supramolecular hydrogel vaccine based on the oncolytic peptide LTX-315, designed to locally deliver a STING agonist and thereby mobilize antitumor immunity against the tumor itself.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4215560006
09AnimalNot a test of LTX-315 aloneOther designMechanism
The LTX‑315 and STING agonist vaccine induced robust T-cell memory.
In plain wordsThe LTX‑315 combination vaccine induced T-cell memory.
Peptide
LTX-315
Outcome
IncreaseT-cell memory
Study
n: not reported in source
LTX-315 and STING agonist hydrogel vaccine
Outcome group
Immune response · Cancer
Source sentences
Summary
Moreover, the vaccine induced robust T-cell memory and systemic antitumor immunity, indicating its potential to prevent tumor recurrence and metastasis.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we report a supramolecular hydrogel vaccine based on the oncolytic peptide LTX-315, designed to locally deliver a STING agonist and thereby mobilize antitumor immunity against the tumor itself.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4215560009
10AnimalNot a test of LTX-315 aloneOther designMechanism
The LTX‑315 and STING agonist vaccine induced systemic antitumor immunity.
In plain wordsThe LTX‑315 combination vaccine induced antitumor immunity throughout the body.
Peptide
LTX-315
Outcome
IncreaseSystemic antitumor immunity
Study
n: not reported in source
LTX-315 and STING agonist hydrogel vaccine
Outcome group
Immune response · Cancer
Source sentences
Summary
Moreover, the vaccine induced robust T-cell memory and systemic antitumor immunity, indicating its potential to prevent tumor recurrence and metastasis.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we report a supramolecular hydrogel vaccine based on the oncolytic peptide LTX-315, designed to locally deliver a STING agonist and thereby mobilize antitumor immunity against the tumor itself.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4215560010
11AnimalNot a test of LTX-315 aloneOther designMechanism
In the LTX‑315 and STING agonist vaccine system, dendritic cells processed tumor antigens under STING-mediated activation.
In plain wordsIn the LTX‑315 combination vaccine system, dendritic cells processed tumor antigens during STING activation.
Peptide
LTX-315
Outcome
Not applicableDendritic cell antigen processing
Study
n: not reported in source
LTX-315 and STING agonist hydrogel vaccine
Outcome group
Immune response · Cancer
Source sentences
Summary
LTX-315 induces immunogenic cell death and facilitates the release of autologous tumor antigens, which are subsequently internalized and processed by dendritic cells (DCs) under STING-mediated activation.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we report a supramolecular hydrogel vaccine based on the oncolytic peptide LTX-315, designed to locally deliver a STING agonist and thereby mobilize antitumor immunity against the tumor itself.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4215560011

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.